AstraZeneca PLC (LON:AZN)
12,640
+186 (1.49%)
Oct 3, 2025, 3:45 PM BST
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.68
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
193.12B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Oxford Nanopore Technologies | 204.69M |
AstraZeneca News
- 22 hours ago - AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy? - The Motley Fool
- 1 day ago - AstraZeneca (AZN) Urged to Consider U.S. Headquarters - GuruFocus
- 1 day ago - AstraZeneca Shares Leap 4.2% on Breakthrough Cancer Drug Approval and Robust Q3 Outlook - ABC Money
- 1 day ago - FTSE 100 hits another high despite concerns over US government shutdown - Evening Standard
- 1 day ago - AstraZeneca (AZN) Among Pharma Giants Facing New Medicare Pricing Plan - GuruFocus
- 2 days ago - AstraZeneca shares leap with FDA set to review drug to treat breast cancer - MarketWatch
- 2 days ago - AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Advances in FDA Review - GuruFocus
- 2 days ago - AstraZeneca (AZN) Advances Cancer Treatment with New License Review - GuruFocus